Loss & Gain Productivity (LGP) of SC Infliximab: Preliminary Data Based on HEOR Model in LMIC/LATAM/Brazil

Author(s)

Tanaka E1, Azevedo VF2, Priszkulnik G3, Santos M4, Barbosa RS5, Silva B6
1TNK Health Economics Outcome Research Brazil, CURITIBA, Brazil, 2Federal University of Paraná, Curitiba, Brazil, 3TNK INSTITUTION, Sao Paulo, Brazil, 4UNESCO Chair of Bioethics - Brasilia University, Sao Paulo, SP, Brazil, 5TNK, SÃO PAULO, Brazil, 6TNK, Santos, SP, Brazil

OBJECTIVES: The innovation of subcutaneously administered infliximab in the global market is resulting in significant economic benefits,reducing PLG and lower administrative costs. In addition offering patients convenience and their caregivers and potential gains PGL. We analyze possible situations avoiding expenses in cases of incorporation or not of innovation.

METHODS: Considering Brazilian population (218 million inhabitants), estimated incidence, prevalence of inflammatory pathologies, such as RHEUMATOID ARTHRITIS ( RA ), INFLAMMATORY BOWEL DISEASES ( IBD ) and PSORIASIS & PSORIATIC ARTHRITIS ( PA ) , were obtained by the respective medical societies dedicated to these diseases. For the purpose of analyzing the research of economic data, we assume the data published and accepted in the international literature, pertinent to our current items of this study.

RESULTS: With the incidence range between 0.5 to 1.0 % for RA & IBD, we obtained 2 180 000 to 4 360 000 cases, and between 1.5 to 2.0 % for PSORIASIS & PA , with 1 635 000 to 4 360 000 cases, in potential for the model under analysis. Assuming that 19.18 % reduction/patient/year ( by international corroborated data ) , when incorporated the innovation , we can reach a total avoidance costs for treat at least 731 717 to 1 672 496 more patients / year ( calculation based on 19.18% of the total incidence variation from 3 815 000 to 8 720 000 ). The refletions of these advantages seems to be proportional to the loss & gain productivity .

CONCLUSIONS: Based on these ( the incidence of these pathologies, using the pharmacoeconomic model with application of results from the international scenario of costs to be avoided with the adoption of innovation ) , we conclude that it is dominant cost effectiveness for this situation. More detailed studies are needed to corroborate other economic advantages , even for to the loss & gain productivity .

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

EE220

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Thresholds & Opportunity Cost

Disease

Biologics & Biosimilars, Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×